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Next-Generation Sequencing Reveals Deep Intronic
Cryptic ABCC8 and HADH Splicing Founder Mutations
Causing Hyperinsulinism by Pseudoexon Activation
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Teoman Akcay,4 Feyza Darendeliler,5 Firdevs Bas,5 Ayla Guven,6 Zeynep Siklar,7 Gonul Ocal,7
Merih Berberoglu,7 Nuala Murphy,8 Maureen O’Sullivan,9,10 Andrew Green,11,12 Peter E. Clayton,13
Indraneel Banerjee,13,14 Peter T. Clayton,15 Khalid Hussain,16,17 Michael N. Weedon,1 and
Sian Ellard1,2,*
Next-generation sequencing (NGS) enables analysis of the human genome on a scale previously unachievable by Sanger sequencing.
Exome sequencing of the coding regions and conserved splice sites has been very successful in the identification of disease-causingmuta-
tions, and targeting of these regions has extended clinical diagnostic testing from analysis of fewer than ten genes per phenotype tomore
than 100. Noncoding mutations have been less extensively studied despite evidence from mRNA analysis for the existence of deep
intronic mutations in >20 genes. We investigated individuals with hyperinsulinaemic hypoglycaemia and biochemical or genetic
evidence to suggest noncoding mutations by using NGS to analyze the entire genomic regions of ABCC8 (117 kb) and HADH (94 kb)
from overlapping ~10 kb PCR amplicons. Two deep intronic mutations, c.1333-1013A>G in ABCC8 and c.636þ471G>T HADH, were
identified. Both are predicted to create a cryptic splice donor site and an out-of-frame pseudoexon. Sequence analysis of mRNA from
affected individuals’ fibroblasts or lymphoblastoid cells confirmed mutant transcripts with pseudoexon inclusion and premature termi-
nation codons. Testing of additional individuals showed that these are founder mutations in the Irish and Turkish populations,
accounting for 14% of focal hyperinsulinism cases and 32% of subjects with HADH mutations in our cohort. The identification of
deep intronic mutations has previously focused on the detection of aberrant mRNA transcripts in a subset of disorders for which
RNA is readily obtained from the target tissue or ectopically expressed at sufficient levels. Our approach of using NGS to analyze the
entire genomic DNA sequence is applicable to any disease.Most intronic mutations occur within or close to con-
served splice sites and are readily detected through Sanger
sequencing of PCR amplicons targeting exons. Deep in-
tronic mutations located >500 bp from an exon were first
reported nearly 30 years ago through studies of cloned
human b-globin (HBB [MIM 613985]).1–3 These base
substitutions create cryptic splice donor or acceptor sites
that result in the inclusion of an out-of-frame pseudoexon,
which leads to a frameshift and premature termination
codon. Over the past three decades, virtually all deep in-
tronic splicing mutations have been identified through
mRNA analysis,4–6 but this requires access to the target
tissue or ectopic expression of aberrant transcripts in
leukocytes and is compromised by the degradation of
mutant transcripts through nonsense-mediated decay.
Next-generation-sequencing (NGS) technology provides
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just the coding exons and conserved splice sites.
We studied a cohort of hyperinsulinaemic-hypoglycae-
mia (HH)-affected subjects in whom there was genetic
evidence to suggest deep intronicmutations. HH is a genet-
ically heterogeneous disorder that if uncontrolled can
cause irreparable brain damage. The hyperinsulinism can
affect the entire pancreas or be confined to a focal
lesion, but these subtypes are clinically indistinguishable.
Focal lesions result from a two-hit mechanism of a pater-
nally inherited ABCC8 (MIM 256450) or KCNJ11 (MIM
601820) mutation and paternal uniparental isodisomy of
chromosomal region 11p15.7,8 The majority of these indi-
viduals do not respond to medical therapy, but surgical
resection of the lesion is curative. In a cohort of 125
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ligation-dependent probe amplification (MLPA) to detect
ABCC8 or KCNJ11mutations in all but two cases with focal
hyperinsulinism.9 The unique mechanism underlying
focal hyperinsulinism suggested the possibility of a deep
intronic ABCC8 mutation in these two cases given that
KCNJ11 has only a single exon.
Individuals with recessive HADH mutations (MIM
609975) have protein-sensitive HH and are treated with
a combination of diazoxide therapy and dietary manage-
ment.10,11 Linkage analysis previously led us to identify
HADHmutations as a common cause of diazoxide-respon-
sive HH in consanguineous pedigrees.12 The 3.3 Mb region
of linkage included HADH, but mutations were only found
in three of the six homozygous probands despite se-
quencing of the coding region, conserved splice sites, alter-
native exons, minimal promoter, and 30 UTR. In one
person, in vitro studies demonstrated a reduction in
HADH activity in cultured skin fibroblasts, consistent
with an undetected HADH mutation (affected individual:
10.9 nmol/min/mg protein; controls [n ¼ 28]: 147.0 5
29.4 nmol/min/mg protein). Since then, we have identi-
fied two further probands with a >3 cM homozygous
region spanning HADH but no coding mutation. All five
probands are of Turkish descent, and genotype analysis
with Affymetrix 6.0 SNP chip (Aros Applied Biotechnology,
Aarhus, Denmark) showed a shared 1.6 Mb haplotype
(chr4: 108,116,751–109,714,172 hg19).
To investigate the possibility of deep intronic mutations
in HADH and ABCC8, we performed NGS of (1) the
93,929 bp (chr4: 108,874,712–108,968,640 hg19) genomic
region of HADH in a proband homozygous for the 1.6 Mb
shared 4q25 haplotype, as well as his unaffected sibling,
and (2) the 116,738 bp (chr11: 17,398,790–17,515,527
hg19) genomic region of ABCC8 in the two unrelated indi-
viduals with a histological diagnosis of focal hyperinsu-
linism but no identified ABCC8 or KCNJ11 mutation.
Informed consent was obtained from all participants or
their parents, and institutional-review-board approval
was received for this study. Peripheral leukocyte DNA was
amplified in 10 (HADH) or 12 (ABCC8) overlapping long-
range PCR reactions with the use of the SequalPrep Long
PCR kit (Life Technologies). After pooling of amplicons
in equimolar quantities, DNA was sheared by sonication
(Diagenode Bioruptor), and fragments in the size range of
200–300 bp were isolated for library preparation with
custom adapters with a 6 base index sequence tag. Indi-
vidual libraries were enriched by 12 cycles of PCR amplifi-
cation and were then pooled in equimolar quantities for
76 bp paired-end sequencing on an Illumina GAII
sequencer. After sequencing, reads for each proband were
sorted with the unique index sequences, the Burrows-
Wheeler Aligner was used for aligning sequence reads to
the hg19 reference genome, and duplicate reads were
removed.13 For the HADH sequencing, 100% percent of
the targeted 93,929 bases were covered with at least 30
reads and had an average coverage of 1,2073. For the
ABCC8 sequencing, 99.6% percent of the targeted132 The American Journal of Human Genetics 92, 131–136, January 1116,738 bases were covered with at least 30 reads and
had an average coverage of 9693. GATK was used for
calling SNVs and indels.14
We identified 123 homozygous variants in the proband
with reduced HADH activity and homozygosity across
HADH (RefSeq accession number NM_005374.4). We
then removed SNPs present in dbSNP132 and the 1000
Genomes Project (November 2011 version), indels that
occurred in homopolymer tracts, and variants that were
homozygous in the unaffected sibling (Table S1, available
online). This left two intronic HADH variants and an inter-
genic change within the chromosome 4 region, and none
of these occurred at highly conserved bases (the genomic
evolutionary rate profiling [GERP] scores were<0). In silico
splicing predictions were investigated with Alamut soft-
ware version 2.1 (Interactive Biosoftware, Rouen, France).
No effect on splicing was predicted for the HADH c.420-
938C>T mutation. However, each of the five splicing
programs (NNSpice, SpliceSiteFinder-like, MaxEntScan,
Human Splicing Finder, and GeneSplicer) accessed by
Alamut predicted the creation of a cryptic splice donor
site resulting from the HADH c.636þ471G>T mutation
(Figure 1). The proband was also homozygous for the
c.636þ385A>G (rs732941) SNP, which creates a predicted
cryptic splice acceptor site (Figure 1). In the presence of
both variants, a 141 bp pseudoexon was predicted (Alamut
software version 2.1, Interactive Biosoftware). In the two
cases with focal hyperinsulinism, we found 83 shared
heterozygous variants, and additional filtering (as above)
yielded a single shared variant, ABCC8 c.1333-1013A>G
(RefSeq NM _000352.3) (Table S2), which was also pre-
dicted to create a cryptic splice donor site (Figure 1) and
a 76 bp pseudoexon (Alamut software version 2.1n, Inter-
active Biosoftware). Both mutations were confirmed by
Sanger sequencing, and testing of the parents identified
heterozygous HADH c.636þ471G>T mutations in both
parents and heterozygous ABCC8 c.1333-1013A>G muta-
tions in the fathers of both focal-hyperinsulinism cases.
To investigate the effect of these variants on splicing, we
derived cell lines from fibroblasts of the person homozy-
gous for the HADH c.636þ471G>T variant and from
Epstein-Barr-virus-transformed peripheral lymphocytes of
a parent heterozygous for the ABCC8 c.1333-1013A>G
variant. Total RNA was extracted and cDNA analysis was
performed with primers targeted to exons 5 and 6 of
HADH or exons 8 and 9 of ABCC8. Figure 2 shows the
sequence electropherograms of the normal and mutant
transcripts. Both cryptic splice-donor-site variants result
in the inclusion of an out-of-frame pseudoexon (141 bp
for HADH; 76 bp for ABCC8), which leads to a frameshift
and premature termination codon. We conclude that
both are pathogenic mutations causing HH.
To seek additional individuals with these cryptic splicing
mutations, we undertook testing for the HADH variant in
a further 56 diazoxide-responsive-HH-affected probands
from consanguineous pedigrees (n ¼ 36) and/or of Turkish
descent (n ¼ 28), including the four other Turkish cases0, 2013
Figure 1. In Silico Splicing Predictions for the Wild-Type and Mutant Genomic Sequences for HADH and ABCC8
The positions of (A) the c.636þ471G>T mutation and c.636þ385A>G (rs732941) SNP in HADH and (B) the c.1333-1013A>G muta-
tion in ABCC8 are indicated by dotted lines. Hits from SpliceSiteFinder-like, MaxEntScan, NNSPLICE, GeneSplicer, and Human
Splicing Finder are displayed as blue vertical bars for 50 (donor) sites and as green vertical bars for 30 (acceptor) sites. The prediction
score is provided beside each bar, and the range of scores for each program is provided in brackets. A high score predicts a
strong splice site.
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Figure 2. Electropherograms Showing
cDNA Sequencing Analysis of PCR Prod-
ucts Amplified with Primers Targeting
Exons 5 and 6 of HADH and Exons 8 and
9 of ABCC8
The nucleotide and amino acid sequences
are provided. A dashed line denotes an
exon-exon boundary.
(A) Sequencing analysis identified a 141 bp
pseudoexon between exons 5 and 6 of
HADH in an affected individual with ho-
mozygosity for the c.636þ471G>T muta-
tion and the c.636þ385A>G (rs732941)
SNP. This pseudoexon introduces a prema-
ture termination codon after seven amino
acids. Sequencing analysis of an unaf-
fected individual homozygous for the
wild-type allele demonstrated normal
splicing of exons 5 and 6.
(B) Sequencing analysis of cDNA from a
parent with the heterozygous c.1333-
1013A>G ABCC8 mutation identified a
76 bp pseudoexon between exons 8 and
9 of ABCC8. This pseudoexon results in
the addition of 25 amino acids, a shift in
the reading frame of exon 9, and a prema-
ture termination codon after residue 4 of
exon 10.known to share the 1.6 Mb haplotype. A homozygous
c.636þ471G>T mutation was found in 8 of the 28 Turkish
individuals, all of whom were also homozygous for the
c.636þ385A>G (rs732941) SNP. Testing for the ABCC8
c.1333-1013A>G variant was performed in an additional
29 diazoxide-unresponsive-HH-affected individuals who
had undergone a pancreatectomy (n ¼ 28) or postmortem
(n ¼ 1) and in whom sequencing of ABCC8 and KCNJ11
and dosage analysis by MLPA had excluded a mutation.
A heterozygous c.1333-1013A>G ABCC8 cryptic splicing
mutation was identified in three further probands with
likely focal disease (mutations were paternally inherited
in two probands, and the third was not inherited mater-
nally, but no sample was available from that proband’s
father). A homozygous c.1333-1013A>G ABCC8mutation
was identified in one person with diffuse disease,
confirmed in the postmortem. Both parents are heterozy-
gous. Four of the six probands with the ABCC8 c.1333-
1013A>G mutation were referred from the Republic of
Ireland. Analysis of chromosome 11 microsatellite markers
demonstrated a minimum shared haplotype of 694 kb
(flanking markers D11S921 and D11S1888) in all six indi-
viduals, suggesting that this is a founder mutation in the
Irish population.
Molecular genetic testing is an essential tool for the clin-
ical management of individuals with HH.15 Identification
of a paternally inherited KCNJ11 or ABCC8 mutation
suggests the likelihood of focal hyperinsulinism, which
can be cured by surgical lesionectomy. In our cohort of
43 individuals with a histological diagnosis of focal hyper-
insulinism, a heterozygous KCNJ11 or ABCC8 mutation
has now been detected in all but one (98%) case, and the
deep intronic mutation, c.1333-1013A>G, accounts for134 The American Journal of Human Genetics 92, 131–136, January 16/43 (14%) cases. We have now included testing for this
mutation in our rapid KCNJ11 and ABCC8 Sanger
sequencing protocol in order to increase the mutation
detection rate and distinguish between focal lesions and
diffuse disease. TheHADH c.636þ471G>T Turkish founder
mutation is the most common HADH mutation in our
cohort and accounts for 9/28 (32%) subjects with HADH
mutations. Leucine hypersensitivity is a feature of HADH
mutations, and a genetic diagnosis highlights the
need for dietary management in addition to diazoxide
therapy.10,11,16
NGS enabled the identification of deep intronic founder
mutations in 15 individuals with HH. We achieved this by
analyzing the entire genomic region (~100 kb) of each
gene in order to find thesemutations, which had not previ-
ously been detected by Sanger sequencing of the ~5 kb
region that includes the exons and conserved splice sites.
This direct analysis of genomic DNA is not subject to the
limitations of mRNA analysis for finding such mutations.
These limitations include access to tissues that express
the gene, the presence of multiple mRNA transcripts, and
degradation of mRNA transcripts containing premature
termination codons. For individuals with HH, any stored
pancreatic tissue has usually been fixed in formalin and
rendered suboptimal for mRNA analysis. We were able to
analyze mRNA from fibroblasts or lymphoblastoid cell
lines, but these were created for our research study and
are not usually available for clinical diagnostic tests.
To our knowledge, there are no reports of whole-genome
sequencing being used for the identification of pathogenic
noncodingmutations. Exome sequencing has proved to be
a successful strategy for identifying coding mutations in
unassociated etiological genes, and our study suggests0, 2013
that analyzing noncoding regions of known genes by tar-
geted NGS might prove useful before starting to search
for mutations in unknown genes. The contribution of
deep intronic mutations to the overall mutation burden
has yet to be determined given that the current estimate
of 0.9% (Human Gene Mutation Database) is based on
partial ascertainment. This category of mutations is of
therapeutic interest because they might be amenable to
correction through antisense therapy.17,18
In this study, we demonstrated the utility of NGS for
identifying deep intronic splicing mutations causing HH.
Sequencing the entire genomic DNA sequence might
increase the diagnostic mutation yield for many other
genetic diseases and could save futile exome-sequencing
studies.Supplemental Data
Supplemental Data include two tables and can be found with this
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